Praxis Medical Insights

Est. 2024 • Clinical Guidelines Distilled

Made possible by volunteer editors from the University of Calgary & University of Alberta

Last Updated: 2/6/2026

Bupropion as a Weight‑Loss‑Promoting Antidepressant

Mechanism of Action

  • Bupropion acts as a norepinephrine‑dopamine reuptake inhibitor; this neurochemical profile suppresses appetite and reduces food cravings, leading to weight loss. 1

Efficacy in Clinical Trials

Short‑Term Weight Reduction

  • In pooled analyses of 6–12‑month randomized trials, patients receiving bupropion experienced an average weight loss of ≈2.8 kg from baseline. (Evidence from multiple RCTs; moderate‑to‑high certainty.) 6
  • An additional meta‑analysis reported a mean weight loss of ≈1.3 kg with bupropion therapy. (Systematic review; moderate certainty.) 4

FDA‑Approved Combination for Weight Management

  • The U.S. Food and Drug Administration approved the bupropion + naltrexone combination (Contrave) in 2014 for chronic weight management, based on demonstrated appetite suppression and craving reduction. (Regulatory approval; high‑quality evidence.) 7

Comparative Weight Effects Among Antidepressants

  • Unique weight‑loss property: Bupropion is the only antidepressant consistently associated with weight loss, distinguishing it from other agents. (Guideline‑based consensus; moderate certainty.) 1
  • Weight‑gaining agents: Antidepressants such as paroxetine, amitriptyline, mirtazapine, nortriptyline, lithium, and monoamine‑oxidase inhibitors are reliably linked to weight gain. (Observational data; moderate certainty.) 1
  • Weight‑neutral agents: Fluoxetine and sertraline may produce modest short‑term weight loss (4–12 weeks) but become weight‑neutral with longer use (>4 months). (Longitudinal cohort data; moderate certainty.) 1

Clinical Recommendations

  • For patients with obesity or concerns about weight gain, bupropion should be considered first‑line when an antidepressant is indicated. (2017 Gastroenterology guideline; strong recommendation.) 1
  • The same Gastroenterology guideline explicitly recommends bupropion as the preferred antidepressant in obese patients because of its weight‑loss effect. (Guideline recommendation; strong.) 1

Safety and Caveats

  • Bupropion’s activating properties can exacerbate anxiety and are contraindicated in individuals with bipolar disorder. (Clinical safety data; moderate certainty.) 1
  • The weight‑loss effect, while modest, is consistently observed across multiple studies, confirming its reproducibility. (Evidence synthesis; moderate certainty.) 6